BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37178682)

  • 1. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification.
    Millen R; De Kort WWB; Koomen M; van Son GJF; Gobits R; Penning de Vries B; Begthel H; Zandvliet M; Doornaert P; Raaijmakers CPJ; Geurts MH; Elias SG; van Es RJJ; de Bree R; Devriese LA; Willems SM; Kranenburg O; Driehuis E; Clevers H
    Med; 2023 May; 4(5):290-310.e12. PubMed ID: 37178682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.
    Perréard M; Florent R; Divoux J; Grellard JM; Lequesne J; Briand M; Clarisse B; Rousseau N; Lebreton E; Dubois B; Harter V; Lasne-Cardon A; Drouet J; Johnson A; Le Page AL; Bazille C; Jeanne C; Figeac M; Goardon N; Vaur D; Micault E; Humbert M; Thariat J; Babin E; Poulain L; Weiswald LB; Bastit V
    BMC Cancer; 2023 Mar; 23(1):223. PubMed ID: 36894916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Imaging of Head and Neck Cancer Organoids.
    Shah AT; Heaster TM; Skala MC
    PLoS One; 2017; 12(1):e0170415. PubMed ID: 28099487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?
    Farshbaf A; Lotfi M; Zare R; Mohtasham N
    Pharmacogenomics J; 2023 May; 23(2-3):37-44. PubMed ID: 36347937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
    Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
    Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.
    Driehuis E; Kolders S; Spelier S; Lõhmussaar K; Willems SM; Devriese LA; de Bree R; de Ruiter EJ; Korving J; Begthel H; van Es JH; Geurts V; He GW; van Jaarsveld RH; Oka R; Muraro MJ; Vivié J; Zandvliet MMJM; Hendrickx APA; Iakobachvili N; Sridevi P; Kranenburg O; van Boxtel R; Kops GJPL; Tuveson DA; Peters PJ; van Oudenaarden A; Clevers H
    Cancer Discov; 2019 Jul; 9(7):852-871. PubMed ID: 31053628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
    You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
    BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
    Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head and neck cancer organoids as a promising tool for personalized cancer therapy: A literature review.
    Mohtasham N; Mohajer Tehran F; Abbaszadeh H
    Health Sci Rep; 2022 Apr; 5(3):e580. PubMed ID: 35387311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
    Kijima T; Nakagawa H; Shimonosono M; Chandramouleeswaran PM; Hara T; Sahu V; Kasagi Y; Kikuchi O; Tanaka K; Giroux V; Muir AB; Whelan KA; Ohashi S; Naganuma S; Klein-Szanto AJ; Shinden Y; Sasaki K; Omoto I; Kita Y; Muto M; Bass AJ; Diehl JA; Ginsberg GG; Doki Y; Mori M; Uchikado Y; Arigami T; Avadhani NG; Basu D; Rustgi AK; Natsugoe S
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):73-91. PubMed ID: 30510992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
    Seol HS; Oh JH; Choi E; Kim S; Kim H; Nam EJ
    J Gynecol Oncol; 2023 May; 34(3):e35. PubMed ID: 36659831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
    Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
    Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
    Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
    Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
    Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
    Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of targeted therapy in the treatment of squamous cell head and neck cancer].
    Gyergyay F
    Magy Onkol; 2007; 51(2):155-7. PubMed ID: 17660872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck.
    Akervall J; Kurnit DM; Adams M; Zhu S; Fisher SG; Bradford CR; Carey TE
    Acta Otolaryngol; 2004 Sep; 124(7):851-7. PubMed ID: 15484403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Derived Organoids of Cholangiocarcinoma.
    Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
    JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.